Yahoo
KOSDAQ - Delayed Quote KRW

LigaChem Biosciences Inc. (141080.KQ)

61,700.00 +200.00 (+0.33%)
At close: 3:30:30 PM GMT+9
Chart Range Bar
Loading chart for 141080.KQ
  • Previous Close 61,500.00
  • Open 60,600.00
  • Bid 61,500.00 x --
  • Ask 61,800.00 x --
  • Day's Range 60,500.00 - 62,400.00
  • 52 Week Range 60,400.00 - 225,000.00
  • Volume 112,350
  • Avg. Volume 235,603
  • Market Cap (intraday) 2.274T
  • Beta (5Y Monthly) 0.59
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date (est.) --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 208,000.00

LigaChem Biosciences Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines for unmet medical needs. The company researches and develops products for various therapeutic areas, including antibiotics, anti-fibrotics, immuno-oncology, oncology; and antibody-drug conjugate (ADC) platform technology and small molecule drugs. It also sells medical device and supplies. It has a research collaboration and license agreement with AMGEN for the development and commercialization of ADCs. The company was formerly known as LegoChem Biosciences, Inc. and changed its name to LigaChem Biosciences Inc. in April 2024. LigaChem Biosciences Inc. was founded in 2006 and is headquartered in Daejeon, South Korea.

ligachembio.com

183

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .

YTD Return

141080.KQ
64.48%
KOSPI Composite Index (^KS11)
39.03%

1-Year Return

141080.KQ
57.86%
KOSPI Composite Index (^KS11)
42.64%

3-Year Return

141080.KQ
60.89%
KOSPI Composite Index (^KS11)
150.05%

5-Year Return

141080.KQ
29.08%
KOSPI Composite Index (^KS11)
94.43%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 5.53B
Earnings -71.2B
Profit Margin -1,286.85%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-60B
-40B
-20B
0
20B
40B
-1200.0%
-1000.0%
-800.0%
-600.0%
-400.0%
-200.0%

Analyst Insights

View More

Analyst Price Targets

150,000.00
208,000.00 Average
61,700.00 Current
230,000.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -180.94%

  • Return on Assets (ttm)

    -19.81%

  • Return on Equity (ttm)

    -36.55%

  • Revenue (ttm)

    98.78B

  • Net Income Avi to Common (ttm)

    -178.73B

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    383.86B

  • Total Debt/Equity (mrq)

    0.59%

  • Levered Free Cash Flow (ttm)

    -144.32B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: